Northwest & Ethical Investments L.P. Boosts Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Northwest & Ethical Investments L.P. boosted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 6.9% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 14,319 shares of the medical research company’s stock after purchasing an additional 919 shares during the quarter. Northwest & Ethical Investments L.P.’s holdings in IQVIA were worth $2,814,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. FMR LLC increased its holdings in IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after purchasing an additional 804,963 shares during the last quarter. Cantillon Capital Management LLC increased its holdings in shares of IQVIA by 12.3% in the 4th quarter. Cantillon Capital Management LLC now owns 2,066,144 shares of the medical research company’s stock valued at $406,018,000 after acquiring an additional 226,017 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after acquiring an additional 583,396 shares during the last quarter. Nordea Investment Management AB increased its holdings in shares of IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock valued at $277,908,000 after acquiring an additional 452,029 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of IQVIA by 3.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,246,890 shares of the medical research company’s stock valued at $245,026,000 after acquiring an additional 44,991 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on IQV. Morgan Stanley boosted their price target on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. William Blair reiterated an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Royal Bank of Canada restated an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research note on Monday, February 10th. StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a research note on Wednesday, March 12th. Finally, Citigroup lowered their price objective on IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research note on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Trading Down 1.5 %

Shares of IQVIA stock opened at $184.13 on Friday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The firm has a market cap of $32.46 billion, a price-to-earnings ratio of 24.55, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50. The business has a fifty day simple moving average of $195.30 and a 200-day simple moving average of $209.18. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $256.29.

IQVIA (NYSE:IQV) last announced its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, equities analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.